Site-specifically labeled CA19.9-targeted immunoconjugates for the PET, NIRF, and multimodal PET/NIRF imaging of pancreatic cancer

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 52, 2015, Pages 15850-15855

  Houghton, Jacob L ^a   Zeglis, Brian M ^a,b   Abdel Atti, Dalya ^a   Aggeler, Robert ^c   Sawada, Ritsuko ^d   Agnew, Brian J ^c   Scholz, Wolfgang W ^d   Lewis, Jason S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b CITY UNIVERSITY OF NEW YORK   (United States)

^c Thermo Fisher Scientific   (United States)

^d Mabvax   (United States)

Author keywords

CA19.9; Molecular imaging; Pancreatic cancer; PET imaging

Indexed keywords

ANTIBODY CONJUGATE; CA 19-9 ANTIGEN; DEFEROXAMINE; DEFEROXAMINE 5B1 ZR 89; DYE; GLYCAN; MONOCLONAL ANTIBODY; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; FLUORESCENT DYE; RADIOISOTOPE; ZIRCONIUM;

ANIMAL EXPERIMENT; ARTICLE; AUTORADIOGRAPHY; BONE; CANCER CELL CULTURE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG DISTRIBUTION; FLUORESCENCE; HEART; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; IN VITRO STUDY; KIDNEY; LARGE INTESTINE; LIVER; LUNG; MOLECULAR IMAGING; MOUSE; MUSCLE; NEAR INFRARED FLUORESCENCE; NONHUMAN; PANCREAS; PANCREAS CANCER; POLYACRYLAMIDE GEL ELECTROPHORESIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SENTINEL LYMPH NODE; SMALL INTESTINE; SPLEEN; STOMACH; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DISEASE MODEL; FEMALE; FLUORESCENCE MICROSCOPY; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; MULTIMODAL IMAGING; NEAR INFRARED SPECTROSCOPY; NUDE MOUSE; PANCREATIC NEOPLASMS; PROCEDURES; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; CA-19-9 ANTIGEN; CELL LINE, TUMOR; DEFEROXAMINE; DISEASE MODELS, ANIMAL; FEMALE; FLUORESCENT DYES; HUMANS; IMMUNOCONJUGATES; MICE, KNOCKOUT; MICE, NUDE; MICROSCOPY, FLUORESCENCE; MOLECULAR STRUCTURE; MULTIMODAL IMAGING; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOISOTOPES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SPECTROSCOPY, NEAR-INFRARED; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS; ZIRCONIUM;

EID: 84952684868     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1506542112     Document Type: Article

References (32)

1. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63(1):11-30.
2. Rahib L, et al. (2014) Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 74(11):2913-2921.
3. Kalser MH, Barkin J, MacIntyre JM (1985) Pancreatic cancer. Assessment of prognosis by clinical presentation. Cancer 56(2):397-402.
4. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60(5):277-300.
5. Cameron JL, Riall TS, Coleman J, Belcher KA (2006) One thousand consecutive pancreaticoduodenectomies. Ann Surg 244(1):10-15.
6. Van Dam GM, et al. (2011) Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: First in-human results. Nat Med 17(10):1315-1319.
7. Keogan MT, et al. (1998) Diagnosis of pancreatic carcinoma: Role of FDG PET. AJR Am J Roentgenol 171(6):1565-1570.
8. Higashi T, et al. (2003) Diagnosis of pancreatic cancer using fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET)-usefulness and limitations in "clinical reality". Ann Nucl Med 17(4):261-279.
9. Frohlich A, et al. (1999) Detection of liver metastases from pancreatic cancer using FDG PET. J Nuclear Med 40(2):250-255.
10. Murakami K (2011) FDG-PET for hepatobiliary and pancreatic cancer: Advances and current limitations. World J Clin Oncol 2(5):229-236.
11. Koyama K, et al. (2001) Diagnostic usefulness of FDG PET for pancreatic mass lesions. Ann Nucl Med 15(3):217-224.
12. Adams GP, et al. (1998) Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu. Br J Cancer 77(9):1405-1412.
13. Holland JP, et al. (2010) 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. J Nuclear Med 51(8):1293-1300.
14. Girgis MD, et al. (2011) Anti-CA19-9 diabody as a PET imaging probe for pancreas cancer. J Surg Res 170(2):169-178.
15. Hussain T, Nguyen QT (2014) Molecular imaging for cancer diagnosis and surgery. Adv Drug Deliv Rev 66:90-100.
16. Sevick-Muraca EM (2012) Translation of near-infrared fluorescence imaging technologies: Emerging clinical applications. Annu Rev Med 63:217-231.
17. Kannagi R, Izawa M, Koike T, Miyazaki K, Kimura N (2004) Carbohydrate-mediated cell adhesion in cancer metastasis and angiogenesis. Cancer Sci 95(5):377-384.
18. Loy TS, Sharp SC, Andershock CJ, Craig SB (1993) Distribution of CA 19-9 in adenocarcinomas and transitional cell carcinomas. An immunohistochemical study of 527 cases. Am J Clin Pathol 99(6):726-728.
19. Makovitzky J (1986) The distribution and localization of the monoclonal antibodydefined antigen 19-9 (CA19-9) in chronic pancreatitis and pancreatic carcinoma. An immunohistochemical study. Virchows Arch B Cell Pathol Incl Mol Pathol 51(6):535-544.
20. Magnani JL, Steplewski Z, Koprowski H, Ginsburg V (1983) Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin. Cancer Res 43(11):5489-5492.
21. Humphris JL, et al. (2012) The prognostic and predictive value of serum CA19.9 in pancreatic cancer. Ann Oncol 23(7):1713-1722.
22. Sugiura T, et al. (2012) Serum CA19-9 is a significant predictor among preoperative parameters for early recurrence after resection of pancreatic adenocarcinoma. J Gastrointest Surg 16(5):977-985.
23. Sawada R, et al. (2011) Human monoclonal antibodies to sialyl-Lewis (CA19.9) with potent CDC, ADCC, and antitumor activity. Clin Cancer Res 17(5):1024-1032.
24. Viola-Villegas NT, et al. (2013) Applying PET to broaden the diagnostic utility of the clinically validated CA19.9 serum biomarker for oncology. J Nuclear Med 54(11):1876-1882.
25. Zeglis BM, et al. (2014) Chemoenzymatic strategy for the synthesis of site-specifically labeled immunoconjugates for multimodal PET and optical imaging. Bioconjug Chem 25(12):2123-2128.
26. Zeglis BM, et al. (2013) Enzyme-mediated methodology for the site-specific radiolabeling of antibodies based on catalyst-free click chemistry. Bioconjug Chem 24(6):1057-1067.
27. Cohen R, Vugts DJ, Stigter-Van Walsum M, Visser GW, Van Dongen GA (2013) Inert coupling of IRDye800CW and zirconium-89 to monoclonal antibodies for single- or dual-mode fluorescence and PET imaging. Nat Protoc 8(5):1010-1018.
28. Holland JP, Sheh Y, Lewis JS (2009) Standardized methods for the production of high specific-activity zirconium-89. Nucl Med Biol 36(7):729-739.
29. Verel I, et al. (2003) 89Zr immuno-PET: Comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies. J Nuclear Med 44(8):1271-1281.
30. Lindmo T, Bunn PA, Jr (1986) Determination of the true immunoreactive fraction of monoclonal antibodies after radiolabeling. Methods Enzymol 121:678-691.
31. Iwamura T, et al. (1992) Correlation between CA19-9 production in vitro and histological grades of differentiation in vivo in clones isolated from a human pancreatic cancer cell line (SUIT-2). J Gastroenterol Hepatol 7(5):512-519.
32. Iwamura T, Katsuki T (1987) Kinetics of carcinoembryonic antigen and carbohydrate antigen 19-9 production in a human pancreatic cancer cell line (SUIT-2). Gastroenterol Jpn 22(5):640-646.